Kala seeks FDA nod for dry eye disease drug

Kala seeks FDA nod for dry eye disease drug

Source: 
Drug Delivery Business News
snippet: 

Kala Pharmaceuticals (NSDQ:KALA) said today that it submitted a new drug application to the FDA for its KPI-121 0.25% topical product designed for patients with dry eye disease.